920000 MISCELLANEOUS THERAPEUTIC AGENTS 929200 OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Date Listed/Coverage Update:	09-Oct-1992
Unit Price:	3.7485
LCA Price:	N/A
MAC Price:	N/A
Unit of Issue:	Unit
Manufacturer:	ABBVIE CORPORATION (ABV)
ATC:	M03AX01
Provincial Drug Schedule:	1
Interchangeable Products:	No

---

Coverage Status:	REGULAR BENEFIT
Applies to Clients of:	Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
Special Authorization Request Form:	N/A
Coverage Criteria:	N/A

Review Status / Past Decisions Indication Reviewing Body Submission Completion Date CDR Recommendation Date Expert Committee Recommendation Date ADBL Effective Date CDR Recommendation Review Status MIGRAINE Common Drug Review 2018/11/16 2019/10/17 View CDR - List with clinical criteria and/or conditions BLADDER, OVERACTIVE Common Drug Review 2013/12/02 2015/04/01 No Change in Benefit Status BLADDER, OVERACTIVE Common Drug Review 2013/12/02 2014/11/12 View CDR - List with clinical criteria and/or conditions MIGRAINE Common Drug Review 2013/08/22 2014/05/28 View CDR - Do not list NEUROGENIC DETRUSOR OVERACTIVITY Common Drug Review 2012/02/07 2012/07/19 View CDR - List with criteria/condition Please select one CDR - List with clinical criteria and/or conditions No Change in Benefit Status CDR - List with clinical criteria and/or conditions CDR - Do not list CDR - List with criteria/condition Indication MIGRAINE Reviewing Body Common Drug Review Submission Completion Date 2018/11/16 CDR Recommendation Date 2019/10/17 Expert Committee Recommendation Date ADBL Effective Date CDR Recommendation View Review Status CDR - List with clinical criteria and/or conditions Indication BLADDER, OVERACTIVE Reviewing Body Common Drug Review Submission Completion Date 2013/12/02 CDR Recommendation Date Expert Committee Recommendation Date ADBL Effective Date 2015/04/01 CDR Recommendation Review Status No Change in Benefit Status Indication BLADDER, OVERACTIVE Reviewing Body Common Drug Review Submission Completion Date 2013/12/02 CDR Recommendation Date 2014/11/12 Expert Committee Recommendation Date ADBL Effective Date CDR Recommendation View Review Status CDR - List with clinical criteria and/or conditions Indication MIGRAINE Reviewing Body Common Drug Review Submission Completion Date 2013/08/22 CDR Recommendation Date 2014/05/28 Expert Committee Recommendation Date ADBL Effective Date CDR Recommendation View Review Status CDR - Do not list Indication NEUROGENIC DETRUSOR OVERACTIVITY Reviewing Body Common Drug Review Submission Completion Date 2012/02/07 CDR Recommendation Date 2012/07/19 Expert Committee Recommendation Date ADBL Effective Date CDR Recommendation View Review Status CDR - List with criteria/condition